Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi achieved

Evotec AG today announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/two-milestones-in-fragment-based-drug-discovery-alliance-with-shionogi-achieved-5030

Weiterlesen

Evotec and APEIRON Biologics start next project on the Cbl-b target

 Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-biologics-start-next-project-on-the-cbl-b-target-5028

Weiterlesen

Acquisition of remaining 30% of Indian Joint Venture from DIL

Evotec AG today announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/acquisition-of-remaining–30-of-indian-joint-venture-from-dil-5024

Weiterlesen

Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease

Evotec AG and Roche AG announced today that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-roche-agree-to-develop-compound-that-could-slow-the-progression-of-alzheimers-disease-5022

Weiterlesen

Ad hoc: Evotec and Roche agree to develop compound that could slow the progression of Alzheimer’s disease

Evotec AG and Roche AG today announced that they have entered into an exclusive world-wide license agreement for the development and commercialisation of Evotec’s MAO-B inhibitor to treat Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-roche-agree-to-develop-compound-that-could-slow-the-progression-of-alzheimers-disease-5597

Weiterlesen

Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received

Evotec AG  today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/pre-clinical–milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-received-5020

Weiterlesen